NCT07105124 - Safety and Tolerability, and PK of Sibeprenlimab in Chinese Healthy Subject | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 18, 2022

Primary Completion Date

February 15, 2023

Study Completion Date

February 15, 2023

Conditions

Healthy Subjects (HS)

Interventions

DRUG

Sibeprenlimab

Sibeprenlimab is being developed for the treatment of immunoglobulin A nephropathy (IgAN), an autoimmune glomerulonephritis characterized by the deposition of immunoglobulin (Ig) A-containing immune complexes in the kidney.

Trial Locations (1)

Unknown

West China Hospital of Sichuan University, Chengdu